Trials / Not Yet Recruiting
Not Yet RecruitingNCT07465198
Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Biocells Medical · Industry
- Sex
- All
- Age
- 35 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo/controlled group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MSCs | IV infusion of 200,000,000 of neuroinduced mesynchimal stem cells at week 1 of the trial period |
| OTHER | Placebo | Intravenous 0.9% saline infusion, volume- and appearance-matched |
Timeline
- Start date
- 2026-09-01
- Primary completion
- 2029-09-01
- Completion
- 2031-03-01
- First posted
- 2026-03-11
- Last updated
- 2026-03-11
Locations
1 site across 1 country: Poland
Source: ClinicalTrials.gov record NCT07465198. Inclusion in this directory is not an endorsement.